The role of inflammatory cells and their proteases in extravascular fibrinolysis

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue 6, 1996, Pages 497-501

  Heiden, Margarethe ^a   Seitz, Rainer ^a   Egbring, Rudolf ^b  

^a PAUL EHRLICH INSTITUT   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

fibrinolysis; inflammation; monocytes macrophages; neutrophilic granulocytes; proteases

Indexed keywords

ELASTASE; PLASMIN; PROTEINASE;

EXTRAVASCULAR SPACE; FIBRINOLYSIS; HUMAN; INFLAMMATORY CELL; MONOCYTE; NEUTROPHIL; PRIORITY JOURNAL; REVIEW;

EID: 0030482175     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-999050     Document Type: Review

References (68)

1. Havemann K, M Gramse: Physiology and pathophysiology of neutral proteinases of human granulocytes. Adv Exp Med Biol 167:1-20, 1984.
2. Starkey PM, AJ Barret, MC Burleigh: The degradation of articular collagen by neutrophil proteinases. Biochim Biophys Acta 483: 386-397, 1977.
3. Janoff A, J Scherer: Mediators of inflammation in leukocyte lysosomes. IX. Elastinolytic activity in granules of human polymorphonuclear leukocytes. J Exp Med 128:1137-1153, 1968.
4. McDonald JA, DG Kelley: Degradation of fibronectin by leukocyte elastase. J Biol Chem 255:8848-8858, 1980.
5. Johnson U, K Ohlsson, I Olson: Effects of granulocyte neutral proteinases on complement components. Scand J Immunol 5:421-426, 1976.
6. Orr FW, J Varani, DL Kreutzer, RM Senior, DA Ward: Digestion of the fifth component of complement by leukocyte enzymes. Am J Pathol 94:75-84, 1979.
7. Taylor JC, IP Crawford, TE Hugli: Limited degradation of the third component of complement by human leukocyte elastase: Partial characterization of C 3 fragments. Biochemistry 16:3390-3396, 1977.
8. Solomon A, M Gramse, K Havemann: Proteolytic cleavage of IgG molecules by neutral proteases of polymorphonuclear leukocytes. Eur J Immunol 8:782-785, 1978.
9. Plow EF, TS Edgington: An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH. J Clin Invest 56:30-38, 1975.
10. Schmidt W, R Egbring, K Havemann: Effect of elastase-like and chymotrypsin-like neutral proteases from human granulocytes on isolated clotting factors. Thromb Res 6:315-326, 1975.
11. Karpati J, K Varadi, S Elödi: Effect of granulocyte proteases on human coagulation factors IX and X. Hoppe-Seyler's Z Physiol Chem 363:521-525, 1982.
12. Jochum M, S Lander, N Heimburger, H Fritz: Effect of human granulocyte elastase on isolated human antithrombin III. Hoppe-Seyler's Z Physiol Chem 362:103-112, 1981.
13. Eckle I, R Seitz, R Egbring, G Kolb, K Havemann: Protein C degradation in vitro by neutrophil elastase. Biol Chem Hoppe-Seyler 372:1007-1013, 1991.
14. Eckle I, R Seitz, R Egbring, G Kolb, K Havemann: Protein S degradation in vitro by neutrophil elastase. Scand J Clin Lab Invest 53:281-288, 1993.
15. 2plasmin inhibitor by neutral proteinases from human leukocytes. Thromb Res 24:479-483, 1981.
16. 2plasmin inhibitor and Cl inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem 257:9849-9854,1982.
17. Turkington PT: Cathepsin G can produce a gla-domainless protein C in vitro. Thromb Res 63:399-406, 1991.
18. Moroz LA: Mini-plasminogen: A mechanism for leukocyte modulation of plasminogen activation by urokinase. Blood 58:97-104, 1981.
19. Drag B, LC Petersen: Activation of pro-urokinase by cathepsin G in the presence of glucosaminoglycans. Fibrinolysis 8:192-199, 1994.
20. Kornecki E, YH Ehrlich, R Egbring, M Gramse, R Seitz, A Eckhardt, H Lukasiewicz, S Niewiarowski: Granulocyte-platelet interactions and platelet fibrinogen receptor exposure. Am J Physiol 255:H651-H658, 1988.
21. Tonnesen MG, MS Klempner, KF Austen, BU Wintroub: Identification of a human neutrophil angiotensin II generating protease as cathepsin G. J Clin Invest 69:25-30, 1969.
22. Wallin R, M Belew, K Ohlsson, T Saldeen: Purification of vasoactive peptides from human fibrinogen degraded by human leukocytes elastase. Thromb Haemostas 46:52-61, 1981.
23. Bingenheimer C, M Gramse, R Egbring, K Havemann: Fibrinogen degradation by two neutral granulocyte proteinases. Influence of calcium on the generation of fibrinogen degradation products with anti-clotting properties. Hoppe-Seyler's Z Physiol Chem 362: 853-863,1982.
24. Prydz H, AC Allison: Tissue thromboplastin activity of isolated monocytes. Thromb Haemostas 39:582-591, 1978.
25. Jordan RE, J Kilpatrick, RM Nelson: Heparin promotes the inactivation of antithrombin by neutrophil elastase. Science 237:777-779, 1987.
26. Nakstadt B, T Lyberg, OH Skjønsberg, NP Boye: Local activation of the coagulation and fibrinolysis systems in lung disease. Thromb Res 57:827-838, 1990.
27. 2Plasmin inhibitor inactivation by human granulocyte elastase. Hoppe-Seyler's Z Physiol Chem 365:19-26, 1984.
28. Rulot H: Intervention des leukocytes dans l'autolyse de la fibrine. Arch Int Physiol 1:152-158, 1904.
29. Riddle JM, MI Barnhart: Ultrastructural study of fibrin dissolution via emigrated polymorphonuclear neutrophils. Am J Pathol 45: 805-823, 1964.
30. Mingers AM, N Heimburger, E Lutz, O Schmidt: Homocygotic and heterocygotic type I plasminogen deficiency in two families - Clinical and haemostasiological findings. Ann Hematol 70 Suppl I:A75, 1995.
31. Bilezikian SB, HL Nossel: Unique pattern of fibrinogen cleavage by human leukocyte proteases. Blood 50:21-28, 1977.
32. Gramse M, EF Plow, SB Bilezikian, K Havemann: Two radioimmunoassays for the detection of elastase-like protease specific fibrinogen degradation products. Int Soc Haematol Eur Afr Div. III:27 (Abstr.), 1979.
33. Seitz R, L Lereh, A Immel, R Egbring: D-dimer test detects both plasmin and neutrophil elastase derived split products. Ann Clin Biochem 32:193-195, 1995.
34. Eckhardt T, M Koch: Fibrinogen-proleolysis in acute myelogenous leukemia. Blut 53:39-48, 1986.
35. Plow EF, M Gramse, K Havemann: A cleavage associated neoantigen for leukocyte elastase degradation products of fibrinogen. J Lab Clin Med 102:858-869, 1983.
36. Wallin R, T Saldeen: Development of a specific radioimmunoassay for determination of peptides derived from human leukocyte elastase degradation of human fibrin(ogen). Thromb Haemostas 58:301 (Abstr.), 1987.
37. Campbell EJ, RM Senior, JA McDonald, DL Cox: Proteolysis by neutrophils: Relative importance of cell-substrate contact and oxidative inactivation of proteinase inhibitors in vitro. J Clin Invest 70:845-852, 1982.
38. Owen LA, MA Campbell, PL Saunes, SS Boukedes, EJ Campbell: Cell surface-bound elastase and cathepsin G on human neutrophils. A novel, nonoxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases. J Cell Biol 131:775-789, 1995.
39. Dvorak HM: Tumors: Wounds that do not heal. N Engl J Med 315: 1650-1659, 1986.
40. Lorente JA, LJ Garcia-Frade, L Landin, R de Pablo, C Torrado, E Renes, A Garcia-Avello: Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 103:1536-1542, 1993.
41. Egbring R, R Seitz, J Leititis, HJ Kesper, R Burghard, L Lerch: Proteinase inhibitor complexes in septicemia, fulminant hepatic-failure and cardiac shock: Value for diagnosis and therapy control in DIC/F syndrome. Behring Inst Mitt 79:87-103, 1986.
42. Takahashi H, W Tatewaki, K Wada, H Niwano, A Shibata: Fibrinolysis and fibrinogenolysis in disseminated intravascular coagulation. Thromb Haemostas 63:340-344, 1990.
43. Nakstadt B, T Lyberg: Immunohistochemical localization of coagulation, fibrinolytic and antifibrinolytic markers in adenocarcinoma of the lung. APMIS 99:981-988, 1991.
44. Rickles FR, GA Hair, RA Zeff, E Lee, RD Bona: Tissue factor expression in human leukocytes and tumor cells. Thromb Haemostas 74:391-395, 1995.
45. Dal Nogare AR, GB Toews: Characteristics of alveolar macrophages in an animal model of resolving pulmonary inflammation. Am Rev Respir Dis 142:660-667, 1990.
46. Seitz R, N Rappe, M Kraus, A Immel, M Wolf, M Maasberg, R Egbring, R Pfab, K Havemann: Activation of coagulation and fibrinolysis in lung cancer patients: Relation to tumor stage and prognosis. Blood Coag Fibrinolysis 4:249-254, 1993.
47. Seitz R, N Rappe, M Kraus, A Immel, M Maasberg, R Egbring: Activation markers of haemostasis in lung cancer. Thromb Haemostas 69:1036 (Abst), 1993.
48. Gabazza E, O Taguxhi, T Yamakami, M Machishi, H Ibata, S Suzuki: Correlation between increased granulocyte elastase release and activation of blood coagulation in patients with lung cancer. Cancer 72:2134-2140,1993.
49. Seitz R, F Leugner, M Katschinski, A Immel, M Kraus, R Egbring, B Göke: Ulcerative colitis and Crohn's disease: Factor XIII, inflammation and haemostasis. Digestion 55:361-367, 1994.
50. Suzuki R, H Toda, Y Takamura: Dynamics of blood coagulation factor XIII in ulcerative colitis and preliminary study of the factor XIII concentrate. Blut 59:162-164, 1989.
51. Lorenz R, M Heinmüller, M Classen, N Tornieporth, T Gain: Substitution of factor XIII: A therapeutic approach to ulcerative colitis. Haemostasis 21:5-9, 1991.
52. Dempfle CE, J Magez, A Röckel, R Gladisch, J Harenberg, DL Heene: Acquired factor XIII deficiency and substitution of factor XIII in exacerbated ulcerative colitis and Crohn's disease. In: McDonagh J, R Seitz, R Egbring (Eds): Factor XIII. Schattauer, Stuttgart, 1993, pp 181-192.
53. Carmassi F, R Uchino, M Cardinali, SI Chung: Influence of factor XIII mediated cross-link on extravascular fibrinolysis. In: McDonagh J, R Seitz, R Egbring (Eds): Factor XIII. Schattauer, Stuttgart, 1993, pp 9-16.
54. Egbring R, WB Schwerk, A Kröniger, A Immel, O Feddersen, R Seitz: Elevated activation marker: Factor XIII-deficiency and severe intestinal haemorrhage in three patients with morbus Henoch-Schoenlein. Blood Coag Fibrinolysis 6:348 (Abst), 1995.
55. Weinberg JB, AMM Pippen, CS Greenberg: Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheumatol 34:996-1005, 1991.
56. 2plasmin inhibitor-plasmin complex in patients with rheumatic disease. Possible role of fibrinolytic mechanisms in vasculitis. Arthritis Rheumatol 32:1427-1433, 1989.
57. Carmassi F, F De Negri, M Morale, R Puccetti, KY Song, SI Chung: Assessment of coagulation and fibrinolysis in synovial fluid of rheumatoid arthritis patients. Fibrinolysis 8:162-171, 1994.
58. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definition for sepsis and organ failure and guidelines for the use of innovative therapy in sepsis. Crit Care Med 20:864-874, 1992.
59. Egbring R, W Schmidt, G Fuchs, K Havemann: Demonstration of granulocyte proteases in plasma of patients with acute leukemia and septicemia with coagulation defects. Blood 49:219-231, 1977.
60. Duswald KH, M Jochum, W Schramm, H Fritz: Released granulocytic elastase: An indicator of pathobiochemical alterations in septicemia after abdominal surgery. Surgery 98:892-899, 1985.
61. Seitz R, R Egbring: Patients with septic shock: Antithrombin III supplementation. Biomed Prog 5:27-29, 1992.
62. Jansen PM, RA Pixley, M Brouwer, IW de Jong, ACK Chang, CCE Hack, FB Taylor, RW Colman: Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 87:2337-2344, 1996.
63. Wachtfogel YT, U Kucich, CE Hack, P Gluszko, S Niewiarowski, RW Colman, LH Edmunds: Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 106:1-9, 1993.
64. Jansen PM, MA Boermeester, E Fischer, IW deJong, T van der Poll, LL Moldawer, CE Hack, SF Lowry: Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: Studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia. Blood 86:1027-1034, 1995.
65. Busch U: Beziehung zwischen Hämostasedefekten und pathologisch-anatomischen Blutungszeichen bei 36 verstorbenen Patienten mit schweren bakteriellen Infektionen. Inauguraldissertation, Philipps-Universität Marburg, 1992.
66. Seitz R, R Egbring, M Wolf, R Wallin, T Saldeen: Elevation of fibrinopeptide Bβ 30-43 (FPBβ 30-43) indicating fibrin(ogen) degradation by neutrophil elastase in septicemia. Thromb Haemostas 62:282 (Abst), 1989.
67. Bos R, CJM van Leuven, J Stolk, PS Hiemstra, JH Dijkman, W Nieuwenhuizen: A monoclonal antibody with high affinity for a neo-antigenic site in fibrinogen degraded by polymorphonuclear leukocyte-derived elastase. Blood Coag Fibrinolysis 6:259-267, 1995.
68. Altieri DC: Proteases and protease receptors in modulation of leukocyte effector functions. J Leukocyte Biol 58:120-127, 1995.